Status:
UNKNOWN
Inpatient Group Acceptance and Commitment Therapy (ACT) for Psychosis Spectrum Disorder
Lead Sponsor:
Vivantes Netzwerk für Gesundheit GmbH
Conditions:
Psychotic Disorders
Acceptance and Commitment Therapy
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The pilot study that will serve as the basis for the larger project - a multicenter randomized controlled single-blinded trial (RCT) will focus on testing the feasibility and efficacy of an inpatient ...
Detailed Description
Inpatient hospitalization is an important time to provide patients with psychosis spectrum disorder with skills to better manage symptoms and improve functioning after discharge. The long-term goal is...
Eligibility Criteria
Inclusion
- Patients with psychosis spectrum disorder with the following diagnoses according to the Diagnostic and Statistical Manual Diploma in Social Medicine 5 ("Schizophrenia Spectrum and Other Psychotic Disorders"):
- Schizophrenia
- Schizophreniform disorder
- Schizoaffective disorder
- Delusional disorder
- Brief psychotic disorder
- Psychotic disorder due to another disorder
- Substance-induced/medication-induced psychotic disorder
- Depressive episode with psychotic symptoms
- Manic or bipolar episode with psychotic symptoms
Exclusion
- Patients decline to participate in the treatment program
- Language or intellectual abilities insufficient for study participation
Key Trial Info
Start Date :
October 16 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2025
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT06086184
Start Date
October 16 2023
End Date
February 1 2025
Last Update
November 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vivantes Klinikum Am Urban
Kreuzberg, State of Berlin, Germany, 10967